person · Reporting owner

GOLDSMITH MARK A

Disclosed activity across 2 companies

Tapewire entity: 19850
SEC CIK: 0001246842

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Revolution Medicines, Inc.RVMD · Entity 606	Director · See Remarks	September 16, 2026	September 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Revolution Medicines, Inc.

Report date September 16, 2026 · Filed September 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	267,117	Reported balance After 2026-09-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-09-16 · Sale · Disposed 213 · Balance 267,117 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Common StockSEC Table I · non-derivative	Direct	253,342	Reported balance After 2026-09-16 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2026-09-16 · Sale · Disposed 13,775 · Balance 253,342 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F3: Includes 157,588 restricted stock units.
Common StockSEC Table I · non-derivative	IndirectTrust	594,060	Reported balance Holding disclosure · report date 2026-09-16 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 594,060 F4: Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
Common StockSEC Table I · non-derivative	IndirectTrust	61,424	Reported balance Holding disclosure · report date 2026-09-16 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 61,424 F5: Held by Jonathan Goldsmith Revocable Trust.
Common StockSEC Table I · non-derivative	IndirectTrust	61,424	Reported balance Holding disclosure · report date 2026-09-16 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 61,424 F6: Held by Rebecca Goldsmith Revocable Trust.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.

F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3: Includes 157,588 restricted stock units.

F4: Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

F5: Held by Jonathan Goldsmith Revocable Trust.

F6: Held by Rebecca Goldsmith Revocable Trust.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CONSTELLATION PHARMACEUTICALS INC

Report date July 15, 2021 · Filed July 19, 2021

Section 16 reporting ended · disclosed 2021-07-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-07-15 transaction · row 1 1 source row Row 1 · 2021-07-15 · Disposition to issuer · Disposed 89,857 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the "Agreement"), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.57	Direct	Reported balance After 2021-07-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-07-15 · Disposition to issuer · Disposed 13,171 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50	Direct	Reported balance After 2021-07-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-07-15 · Disposition to issuer · Disposed 6,825 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.12	Direct	Reported balance After 2021-07-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-07-15 · Disposition to issuer · Disposed 13,171 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60	Direct	Reported balance After 2021-07-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-07-15 · Disposition to issuer · Disposed 12,446 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.51	Direct	Reported balance After 2021-07-15 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-07-15 · Disposition to issuer · Disposed 9,083 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.52	Direct	Reported balance After 2021-07-15 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-07-15 · Disposition to issuer · Disposed 13,171 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the "Agreement"), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 16, 2026 Filed Sep 18, 2026 22:02 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	13,775	$199.30	$2,745,401.58	Disclosure SEC source: 0001246842-26-000008 · ownership.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 253,342 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F3 · balance_after: Includes 157,588 restricted stock units. Read SEC document
September 16, 2026 Filed Sep 18, 2026 22:02 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	213	$195.01	$41,536.81	Disclosure SEC source: 0001246842-26-000008 · ownership.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 267,117 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F2 · price: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	80,000	$0.00 Strike: $4.73	$0.00	Disclosure SEC source: 0001610717-26-000387 · form4.xml · derivative · entry 21 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 344,085 Underlying: Common Stock · 80,000 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on May 22, 2026. Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	126	$212.06	$26,720.08	Disclosure SEC source: 0001610717-26-000387 · form4.xml · nonDerivative · entry 19 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 61,424 F15 · price: This transaction was executed in multiple trades at prices ranging from $212.00 to $212.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F16 · ownership.nature: Held by Rebecca Goldsmith Revocable Trust. Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	229	$211.46	$48,425.44	Disclosure SEC source: 0001610717-26-000387 · form4.xml · nonDerivative · entry 18 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 61,550 F14 · price: This transaction was executed in multiple trades at prices ranging from $210.93 to $211.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F16 · ownership.nature: Held by Rebecca Goldsmith Revocable Trust. Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	126	$210.40	$26,510.78	Disclosure SEC source: 0001610717-26-000387 · form4.xml · nonDerivative · entry 17 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 61,779 F13 · price: This transaction was executed in multiple trades at prices ranging from $209.87 to $210.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F16 · ownership.nature: Held by Rebecca Goldsmith Revocable Trust. Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	1,405	$209.27	$294,019.29	Disclosure SEC source: 0001610717-26-000387 · form4.xml · nonDerivative · entry 16 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 61,905 F18 · price: This transaction was executed in multiple trades at prices ranging from $208.80 to $209.63. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F16 · ownership.nature: Held by Rebecca Goldsmith Revocable Trust. Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	937	$208.36	$195,234.16	Disclosure SEC source: 0001610717-26-000387 · form4.xml · nonDerivative · entry 15 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 63,310 F17 · price: This transaction was executed in multiple trades at prices ranging from $207.80 to $208.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F16 · ownership.nature: Held by Rebecca Goldsmith Revocable Trust. Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	177	$207.25	$36,683.52	Disclosure SEC source: 0001610717-26-000387 · form4.xml · nonDerivative · entry 14 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 64,247 F9 · price: This transaction was executed in multiple trades at prices ranging from $206.78 to $207.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F16 · ownership.nature: Held by Rebecca Goldsmith Revocable Trust. Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	127	$212.06	$26,932.06	Disclosure SEC source: 0001610717-26-000387 · form4.xml · nonDerivative · entry 13 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 61,424 F15 · price: This transaction was executed in multiple trades at prices ranging from $212.00 to $212.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10 · ownership.nature: Held by Jonathan Goldsmith Revocable Trust. Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	245	$211.47	$51,808.95	Disclosure SEC source: 0001610717-26-000387 · form4.xml · nonDerivative · entry 12 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 61,551 F14 · price: This transaction was executed in multiple trades at prices ranging from $210.93 to $211.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10 · ownership.nature: Held by Jonathan Goldsmith Revocable Trust. Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	136	$210.40	$28,614.63	Disclosure SEC source: 0001610717-26-000387 · form4.xml · nonDerivative · entry 11 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 61,796 F13 · price: This transaction was executed in multiple trades at prices ranging from $209.87 to $210.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10 · ownership.nature: Held by Jonathan Goldsmith Revocable Trust. Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	1,351	$209.28	$282,738.90	Disclosure SEC source: 0001610717-26-000387 · form4.xml · nonDerivative · entry 10 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 61,932 F12 · price: This transaction was executed in multiple trades at prices ranging from $208.84 to $209.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10 · ownership.nature: Held by Jonathan Goldsmith Revocable Trust. Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	951	$208.36	$198,154.92	Disclosure SEC source: 0001610717-26-000387 · form4.xml · nonDerivative · entry 9 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 63,283 F11 · price: This transaction was executed in multiple trades at prices ranging from $207.84 to $208.82. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10 · ownership.nature: Held by Jonathan Goldsmith Revocable Trust. Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	190	$207.25	$39,376.63	Disclosure SEC source: 0001610717-26-000387 · form4.xml · nonDerivative · entry 8 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 64,234 F9 · price: This transaction was executed in multiple trades at prices ranging from $206.78 to $207.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10 · ownership.nature: Held by Jonathan Goldsmith Revocable Trust. Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	3,621	$212.08	$767,932.99	Disclosure SEC source: 0001610717-26-000387 · form4.xml · nonDerivative · entry 7 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 267,330 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on May 22, 2026. F8 · price: This transaction was executed in multiple trades at prices ranging from $211.82 to $212.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 182,938 restricted stock units. Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	6,583	$211.33	$1,391,205.80	Disclosure SEC source: 0001610717-26-000387 · form4.xml · nonDerivative · entry 6 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 270,951 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on May 22, 2026. F7 · price: This transaction was executed in multiple trades at prices ranging from $210.81 to $211.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 182,938 restricted stock units. Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	3,813	$210.25	$801,670.29	Disclosure SEC source: 0001610717-26-000387 · form4.xml · nonDerivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 277,534 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on May 22, 2026. F6 · price: This transaction was executed in multiple trades at prices ranging from $209.80 to $210.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 182,938 restricted stock units. Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	35,938	$209.26	$7,520,439.79	Disclosure SEC source: 0001610717-26-000387 · form4.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 281,347 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on May 22, 2026. F5 · price: This transaction was executed in multiple trades at prices ranging from $208.80 to $209.78. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 182,938 restricted stock units. Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	24,917	$208.37	$5,191,947.81	Disclosure SEC source: 0001610717-26-000387 · form4.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 317,285 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on May 22, 2026. F4 · price: This transaction was executed in multiple trades at prices ranging from $207.79 to $208.78. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 182,938 restricted stock units. Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	5,128	$207.23	$1,062,690.82	Disclosure SEC source: 0001610717-26-000387 · form4.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 342,202 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on May 22, 2026. F3 · price: This transaction was executed in multiple trades at prices ranging from $206.78 to $207.7750. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 182,938 restricted stock units. Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	80,000	$4.73	$378,400.00	Disclosure SEC source: 0001610717-26-000387 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 347,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on May 22, 2026. F2 · balance_after: Includes 182,938 restricted stock units. Read SEC document
June 16, 2026 Filed Jun 18, 2026 20:11 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	10,020	$156.12	$1,564,310.38	Disclosure SEC source: 0001610717-26-000246 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 267,330 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8250. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes 182,938 restricted stock units. F4 · balance_after: Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026. Read SEC document
April 15, 2026 Filed Apr 17, 2026 23:26 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	96,756	$0.00 Strike: $4.73	$0.00	Disclosure SEC source: 0001610717-26-000146 · form4.xml · derivative · entry 8 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 424,085 Underlying: Common Stock · 96,756 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. Read SEC document
April 15, 2026 Filed Apr 17, 2026 23:26 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	23,244	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001610717-26-000146 · form4.xml · derivative · entry 7 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,464 Underlying: Common Stock · 23,244 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. Read SEC document
April 15, 2026 Filed Apr 17, 2026 23:26 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	120,000	$150.09	$18,010,488.00	Disclosure SEC source: 0001610717-26-000146 · form4.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 276,698 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $150.00 to $150.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 201,150 restricted stock units. Read SEC document
April 15, 2026 Filed Apr 17, 2026 23:26 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	96,756	$4.73	$457,655.88	Disclosure SEC source: 0001610717-26-000146 · form4.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 396,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F2 · balance_after: Includes 201,150 restricted stock units. Read SEC document
April 15, 2026 Filed Apr 17, 2026 23:26 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	23,244	$4.09	$95,067.96	Disclosure SEC source: 0001610717-26-000146 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 299,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F2 · balance_after: Includes 201,150 restricted stock units. Read SEC document
March 17, 2026 Filed Mar 19, 2026 22:56 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	12,871	$99.48	$1,280,412.23	Disclosure SEC source: 0001610717-26-000130 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 276,698 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 201,150 RSUs. Read SEC document
March 02, 2026 Filed Mar 4, 2026 02:09 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001610717-26-000082 · form4.xml · derivative · entry 18 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,708 Underlying: Common Stock · 30,000 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Includes 225,863 restricted stock units. Read SEC document
March 02, 2026 Filed Mar 4, 2026 02:09 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	200	$102.08	$20,416.00	Disclosure SEC source: 0001610717-26-000082 · form4.xml · nonDerivative · entry 16 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 64,424 F14 · ownership.nature: Held by Rebecca Goldsmith Revocable Trust. Read SEC document
March 02, 2026 Filed Mar 4, 2026 02:09 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	2,100	$101.63	$213,431.61	Disclosure SEC source: 0001610717-26-000082 · form4.xml · nonDerivative · entry 15 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 64,624 F16 · price: This transaction was executed in multiple trades at prices ranging from $101.07 to $102.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F14 · ownership.nature: Held by Rebecca Goldsmith Revocable Trust. Read SEC document
March 02, 2026 Filed Mar 4, 2026 02:09 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	600	$100.19	$60,115.98	Disclosure SEC source: 0001610717-26-000082 · form4.xml · nonDerivative · entry 14 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 66,724 F15 · price: This transaction was executed in multiple trades at prices ranging from $99.80 to $100.71. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F14 · ownership.nature: Held by Rebecca Goldsmith Revocable Trust. Read SEC document
March 02, 2026 Filed Mar 4, 2026 02:09 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	100	$98.29	$9,829.00	Disclosure SEC source: 0001610717-26-000082 · form4.xml · nonDerivative · entry 13 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 67,324 F14 · ownership.nature: Held by Rebecca Goldsmith Revocable Trust. Read SEC document
March 02, 2026 Filed Mar 4, 2026 02:09 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	800	$102.00	$81,598.64	Disclosure SEC source: 0001610717-26-000082 · form4.xml · nonDerivative · entry 12 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 64,424 F13 · price: This transaction was executed in multiple trades at prices ranging from $101.82 to $102.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10 · ownership.nature: Held by Jonathan Goldsmith Revocable Trust. Read SEC document
March 02, 2026 Filed Mar 4, 2026 02:09 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	1,700	$101.47	$172,506.31	Disclosure SEC source: 0001610717-26-000082 · form4.xml · nonDerivative · entry 11 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 65,224 F12 · price: This transaction was executed in multiple trades at prices ranging from $100.81 to $101.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10 · ownership.nature: Held by Jonathan Goldsmith Revocable Trust. Read SEC document
March 02, 2026 Filed Mar 4, 2026 02:09 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	400	$100.12	$40,049.00	Disclosure SEC source: 0001610717-26-000082 · form4.xml · nonDerivative · entry 10 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 66,924 F11 · price: This transaction was executed in multiple trades at prices ranging from $99.79 to $100.71. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10 · ownership.nature: Held by Jonathan Goldsmith Revocable Trust. Read SEC document
March 02, 2026 Filed Mar 4, 2026 02:09 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	100	$98.31	$9,831.00	Disclosure SEC source: 0001610717-26-000082 · form4.xml · nonDerivative · entry 9 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 67,324 F10 · ownership.nature: Held by Jonathan Goldsmith Revocable Trust. Read SEC document
March 02, 2026 Filed Mar 4, 2026 02:09 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	851	$102.20	$86,971.69	Disclosure SEC source: 0001610717-26-000082 · form4.xml · nonDerivative · entry 7 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 289,569 F3 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F8 · price: This transaction was executed in multiple trades at prices ranging from $102.14 to $102.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 225,863 restricted stock units. Read SEC document
March 02, 2026 Filed Mar 4, 2026 02:09 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	21,329	$101.60	$2,167,075.46	Disclosure SEC source: 0001610717-26-000082 · form4.xml · nonDerivative · entry 6 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 290,420 F3 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F7 · price: This transaction was executed in multiple trades at prices ranging from $101.14 to $102.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 225,863 restricted stock units. Read SEC document
March 02, 2026 Filed Mar 4, 2026 02:09 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	3,620	$100.73	$364,659.25	Disclosure SEC source: 0001610717-26-000082 · form4.xml · nonDerivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 311,749 F3 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F6 · price: This transaction was executed in multiple trades at prices ranging from $100.14 to $101.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 225,863 restricted stock units. Read SEC document
March 02, 2026 Filed Mar 4, 2026 02:09 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	3,500	$99.76	$349,150.20	Disclosure SEC source: 0001610717-26-000082 · form4.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 315,369 F3 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F5 · price: This transaction was executed in multiple trades at prices ranging from $99.12 to $100.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 225,863 restricted stock units. Read SEC document
March 02, 2026 Filed Mar 4, 2026 02:09 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	700	$98.17	$68,719.56	Disclosure SEC source: 0001610717-26-000082 · form4.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 318,869 F3 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $97.83 to $98.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 225,863 restricted stock units. Read SEC document
March 02, 2026 Filed Mar 4, 2026 02:09 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	30,000	$4.09	$122,700.00	Disclosure SEC source: 0001610717-26-000082 · form4.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 319,569 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F1 · balance_after: Includes 225,863 restricted stock units. Read SEC document
March 01, 2026 Filed Mar 4, 2026 02:09 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantStock Option (Right to Buy) · Derivative	128,600	$0.00 Strike: $102.02	$0.00	Disclosure SEC source: 0001610717-26-000082 · form4.xml · derivative · entry 17 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,600 Underlying: Common Stock · 128,600 shares Expires 2036-02-28 F17 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document
March 01, 2026 Filed Mar 4, 2026 02:09 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantCommon Stock	57,100	$0.00	$0.00	Disclosure SEC source: 0001610717-26-000082 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 289,569 F1 · balance_after: Includes 225,863 restricted stock units. F2 · balance_after: Reflects the transfer of 24,010 shares to the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust. Read SEC document
February 06, 2026 Filed Feb 10, 2026 22:30 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	24,010	$0.00 Strike: $0.54	$0.00	Disclosure SEC source: 0001610717-26-000048 · form4.xml · derivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,493 Underlying: Common Stock · 24,010 shares Expires 2028-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 06, 2026 Filed Feb 10, 2026 22:30 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	24,010	$0.54	$12,965.40	Disclosure SEC source: 0001610717-26-000048 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 168,763 restricted stock units. Read SEC document
December 16, 2025 Filed Dec 18, 2025 21:17 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	15,394	$76.82	$1,182,525.52	Disclosure SEC source: 0001610717-25-000423 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 232,469 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 168,763 restricted stock units. Read SEC document
November 25, 2025 Filed Nov 26, 2025 21:15 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	60,000	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001610717-25-000403 · form4.xml · derivative · entry 6 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,708 Underlying: Common Stock · 60,000 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.